GLP-1 drugs and influencer weight loss: what the science says

What did @insideedition actually say?

The report covers lifestyle influencer Janelle Rohner, who sold a $200 weight loss program while privately using a GLP-1 medication for roughly a year without disclosing it. Inside Edition framed this as a transparency failure, comparing it to "selling hair growth supplements but secretly wearing extensions." That analogy is apt and the core reporting holds up.

Rohner confirmed she worked with a doctor who recommended adding a GLP-1 to her plan. She named Ozempic, Mounjaro, and Wegovy as examples of what GLP-1 drugs are. The video doesn't claim GLP-1s are dangerous, doesn't recommend dosages, and doesn't dismiss the medications. It focuses almost entirely on the ethics of non-disclosure, which is a legitimate consumer protection story, not a medical one. On that narrow question, Inside Edition is on solid ground.

Does the science back this up?

Here's the part the video glosses over: GLP-1 receptor agonists are legitimately effective. They aren't a shortcut that cancels out diet and exercise. Research shows the combination of GLP-1 medication plus lifestyle intervention outperforms either approach alone.

The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) found semaglutide 2.4mg produced an average 14.9% body weight reduction over 68 weeks, but participants were also following a reduced-calorie diet and exercise program. A 2023 meta-analysis in Obesity Reviews (Shi et al.) confirmed that adding structured lifestyle intervention to GLP-1 therapy improved outcomes beyond medication alone. This matters because Rohner's meal prep and workout content wasn't fake. The drug didn't make those behaviors irrelevant. It likely made them more sustainable by reducing appetite and food noise. Framing GLP-1 use as inherently deceptive about diet and exercise results misses this nuance.

What did they get wrong (or right)?

They got the ethics story right. Selling a $200 program built on the implicit premise that your results come purely from diet and exercise, while privately using a prescription weight loss drug, is a meaningful omission. The FTC's 2023 guidelines on endorsements require that material connections, including anything that could affect how an audience evaluates a claim, be disclosed clearly. A prescribed medication that meaningfully changes appetite and metabolism almost certainly qualifies.

What they got partially wrong is the implied framing that GLP-1 use invalidates the lifestyle work. The video doesn't say this outright, but the "hair extensions" analogy suggests the drug was doing the heavy lifting while the workouts were window dressing. That's not what the evidence shows. GLP-1s suppress appetite and reduce caloric intake. They don't go to the gym. Rohner's exercise content may have been entirely genuine and effective in combination with the medication. The ethical problem is non-disclosure, not the drug use itself.

What should you actually know?

GLP-1 receptor agonists are FDA-approved medications prescribed for weight management and type 2 diabetes. Wegovy (semaglutide 2.4mg) received FDA approval for chronic weight management in adults in 2021. Zepbound (tirzepatide) followed in 2023. These are not supplements or hacks. They require a prescription and ongoing medical supervision.

They also don't work in isolation. A 2022 study in Nature Medicine (Rubino et al.) showed that stopping semaglutide without maintaining lifestyle changes resulted in significant weight regain within a year. The lifestyle behaviors Rohner was promoting, meal prep, structured exercise, protein targets, are consistent with how GLP-1 therapy is actually supposed to work. The problem was the audience didn't have the full picture to evaluate her results or decide whether a $200 program was worth buying. That's the real issue here, informed consent in a commercial context, not whether GLP-1 drugs are legitimate.

Is there a broader pattern worth knowing about?

Rohner is not an isolated case. A 2023 survey by Truveta Research found that GLP-1 prescriptions grew over 300% between 2020 and 2023, with a significant share going to people without a diabetes diagnosis. As the drugs became more common, so did quiet use among influencers in fitness and wellness spaces who built audiences on the premise of "natural" results.

The disclosure gap matters because it shapes what audiences believe is achievable without medication. That affects real decisions, whether to buy a program, whether to feel like a failure for not matching someone else's results, and whether to ask a doctor about options that might actually help. If you're comparing your results to someone else's and feel like you're falling short, it's worth asking whether you have the full picture.